tiotropium Articles
US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018
10 April 2013
Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma patients
25 February 2013
Forest launches COPD product Tudorza in USA
12 December 2012
New LABA/LAMA drugs set to fracture COPD market
10 October 2012
COPD market to grow to more than $13.4 billion in 2020
19 December 2011
Novartis’ Onbrez Breezhaler beats Spiriva in new study of COPD patients; Afinitor reduces SEGAs size
4 November 2010
Spiriva a possible alternative therapy for adults with poorly controlled asthma; Daxas reduces harmful lung attacks, ERS conference hears
21 September 2010
US FDA backs safety of Pfizer/Boehringer’s Spiriva HandiHaler; Pfizer admits EU investigation; gets sued over Chantix
15 January 2010
Roche enters COPD sector with 400 million-plus-euro deal with Galapagos and antibody accord with AnaptysBio
12 January 2010
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
“Novartis aims big in COPD market,” say Zacks analysts
17 September 2009
Boehringer's 2008 net sales jump 6.4%
24 April 2009
Almirall's nine-month profit jumps 5.3%
24 November 2008
Forest Labs' profit up 8% on AD drug sales
10 November 2008
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
27 October 2008
Almirall defies critics to progress COPD drug
27 October 2008
Sosei/Vectura drug may act faster than Spiriva
13 October 2008
UPLIFT data causes stir at Berlin ERS
13 October 2008
Stock Commentary - New York week to Oct 6, 2008
13 October 2008
Boeh Ing and Pfizer deny study's claims that Spiriva causes increased risk of heart attack
29 September 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
Almirall tumbles 42% as COPD drug disappoints
15 September 2008
Boehringer's first-half 2008 profit drops 10%
18 August 2008
Boehringer's first-half 2008 profit drops 10%
18 August 2008
EU's pediatric drug c'tee celebrates first birthday
28 July 2008
Spiriva and Micardis boost Boehringer's 2007 sales 8.8%, as profit jumps 4.8% to $2.8M
14 April 2008
Almirall's COPD drug aclidinium bromide is a potential jewel in the company's crown
10 December 2007
Boeh Ing's 1st half 2007 sales up 2.1%
6 August 2007
Spiriva Respimat OKed for COPD in Europe
30 July 2007
Pharmaxis begins enrollment in Aridol COPD study
21 May 2007
Boeh Ingelheim sales leap 17.3% in Japan
23 April 2007
BI/Pfizer's Spiriva improves lung function in mild COPD
11 September 2006
Record growth for Boeh Ing Japan
1 May 2006
COPD market set to grow 9% a year to reach $12B by 2014
17 April 2006
NZ Pharmac gets budget boost, OKs new Rx uses
8 August 2005
New drugs boost BI's 1st-half sales 22%
8 August 2005
UPDATE: Pfizer withdraws support for Altana's lung drug Daxas on mediocre trial results
11 July 2005
Boeh Ingelheim posts good results for COPD inhaler
18 April 2005
Pfizer and BI's Spiriva reduces COPD exacerbations significantly
13 September 2004
BI 1st-half sales up 7%
23 August 2004
Spiriva set to capture 50% US Rx COPD market share?
19 July 2004
BI's Spiriva cleared for COPD by FDA
9 February 2004
Stock Commentary - New York
9 February 2004
Boeh Ing implores Germany to rewaed innovation after $285M R&D expansion
29 September 2003
BI hit by costs and currencies in first half
11 August 2003
Majors rush to roll out new drugs in Japan
14 July 2003
Spiriva superior to salmeterol in COPD?
12 May 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Boehringer Ingelheim's operating income up 48% in first half; Spiriva prospects strong
19 August 2002
Spiriva launched in first markets
10 June 2002
Tiotropium ups exercise endurance in COPD
27 May 2002
BI's Spiriva cleared for COPD in EU
22 April 2002
Stock Commentary - New York
4 February 2002
Novartis' Foradil cleared for COPD in USA; new data on Xolair
27 September 2001
New Spiriva data reinforce profile of potential COPD blockbuster
26 September 2001
AstraZeneca: Crestor filed, Viozan pulled
28 June 2001
Showing 1-88 of 88 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
